Consciousness Recovery by Rituximab after Seizure Control in Cryptogenic New-Onset Refractory Status Epilepticus

Journal of Neurocritical Care

Jeong Won Jo¹  Do-Hyung Kim²  Oh-Young Kwon²  Young-Soo Kim²  Tae-Won Yang³ 

[1] Department of Dermatology, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea;Department of Neurology and Institute of Health Science, Gyeongsang National University College of Medicine, Jinju, Korea;Department of Neurology, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea;

关键词: Status epilepticus;    Immunotherapy;    Rituximab;    Consciousness;   

DOI  :  10.18700/jnc.180066

来源: DOAJ

【 摘 要 】

Background New-onset refractory status epilepticus (NORSE) occurs in people without a history of seizures. In these cases, the seizure causes are unclear, and the seizures are not controlled by standard treatment. Autoimmune encephalitis (AIE) can be a cause of NORSE. Cryptogenic NORSE may be associated with AIE, but antibodies associated with the condition have not yet been identified. Primary immunotherapy may not be effective for AIE. Rituximab has improved the prognosis in some cases. Case Report We treated a cryptogenic NORSE patient with a combination of antiepileptic drugs and immunotherapy. On the 13th hospital day, the seizures were controlled, but the patient remained in a coma. The patient rapidly recovered after administration of rituximab started on the 26th hospital day. Conclusion Rituximab may be helpful for cryptogenic NORSE patients in whom primary immunotherapy controls seizures, but fails to improve consciousness.

【 授权许可】

Unknown